Lutherville, MD, United States of America

Weiming Luo


 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Location History:

  • Baltimore, MD (US) (2019)
  • Lutherville, MD (US) (2015 - 2022)

Company Filing History:


Years Active: 2015-2022

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Weiming Luo: Innovator in Thalidomide Analog Research

Introduction

Weiming Luo is a notable inventor based in Lutherville, MD (US), recognized for his contributions to the field of medicinal chemistry. He holds a total of seven patents, showcasing his innovative approach to drug development and therapeutic applications.

Latest Patents

Among his latest patents are the "Thalidomide analogs and methods of use." These patents disclose various thalidomide analogs and methods for utilizing these compounds. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Additionally, certain embodiments of these compounds are noted to be non-teratogenic, highlighting their potential safety in therapeutic applications.

Career Highlights

Weiming Luo has had a distinguished career, working with prominent institutions such as the National Institutes of Health, a component of the US Department of Health & Human Services. He has also been associated with the University Court of the University of Aberdeen, where he contributed to significant research initiatives.

Collaborations

Throughout his career, Weiming has collaborated with esteemed colleagues, including David Tweedie and Nigel H Greig. These collaborations have further enriched his research and innovation in the field.

Conclusion

Weiming Luo's work in developing thalidomide analogs demonstrates his commitment to advancing medical science. His patents reflect a significant contribution to therapeutic research, particularly in anti-inflammatory and anti-angiogenic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…